Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.

TitleCost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
Publication TypeJournal Article
Year of Publication2007
AuthorsNeeser, K, Szucs, T, Bulliard, J-L, Bachmann, G, Schramm, W
JournalValue Health
Volume10
Issue1
Pagination42-53
Date Published2007 Jan-Feb
DOI10.1111/j.1524-4733.2006.00143.x
ISSN1098-3015
KeywordsAdult, Aged, Aged, 80 and over, Breast Neoplasms, Cost-Benefit Analysis, Female, Health Care Costs, Humans, Life Expectancy, Mammography, Markov Chains, Mass Screening, Middle Aged, Models, Econometric, National Health Programs, Quality Assurance, Health Care, Quality-Adjusted Life Years, Switzerland, Value of Life
Abstract

OBJECTIVES: Quality-controlled mammography screening programs (MSP) have led to a reduction in breast cancer mortality. The purpose of this economic analysis was to assess the cost-effectiveness of MSP compared with an established opportunistic screening strategy (OS) in Switzerland, to identify the major factors influencing the economic outcome.

METHODS: Using cancer registries and clinical data, a Markov-based decision model was designed to compare MSP with OS in the Swiss female population, considering the main screening-specific performance parameters.

RESULTS: The discounted incremental life expectancy amounted to 0.022 life-years gained in favor of MSP when screening started at age 40 years and decreased to 0.008 years at the age of 70 years (number needed to screen to avoid one death over 10 years ranged from 10,000 to 2439 women depending on the baseline age). The total discounted life-time cost for screening, treatment at the baseline age of 40 years amounted in MSP to $4366 (OS: $2802) and decreased with the baseline age of 70 years to $2412 (OS: $1446). The discounted incremental cost-effectiveness ratio comparing MSP versus OS ranged from $73,018 (age 40 years) to $118,193 (age 70 years) per life-year gained. Testing all model variables confirmed that both incidence and mortality of breast cancer play the most important role in the health economic outcome, whereas cost and performances (sensitivity, specificity) of screening had a minor impact on the efficiency.

CONCLUSION: This analysis, performed under conservative assumptions, supports that MSP in Switzerland enables a relevant reduction of breast cancer mortality, at moderate additional cost, compared with OS.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/17261115?dopt=Abstract

Alternate JournalValue Health
Citation Key / SERVAL ID2478
PubMed ID17261115

                         

IUMSP | www.iumsp.ch
Institute of Social and Preventive Medicine
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top